{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:50:17Z","timestamp":1792183817311,"version":"4.4.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25gk0210045"],"award-info":[{"award-number":["JP25gk0210045"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Vaccine-related myocarditis (VRM) has gained attention during the global roll-out of COVID-19 vaccines. COVID-19 VRM is usually non-fatal, but factors associated with fatal outcomes remain unclear. We aimed to characterize features associated with reported fatal outcomes using a pharmacovigilance database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed COVID-19 VRM reports in the Japanese Adverse Drug Event Report database from 2021 to 2024. Reports were stratified into death and survival groups based on recorded outcome information. Logistic regression analyses identified factors associated with reported fatal outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>31 022 reports listed COVID-19 vaccines as suspected drug; 1041 reports included myocarditis [reporting odds ratio (ROR) 31.3, 95% CI 29.0\u201333.8]. The median time from vaccination to myocarditis onset was 2 (1\u20134) days, with most events occurring within 7 days. Among reports with VRM, men accounted for the majority (77.8%) and 68.6% were \u226439 years old. Outcome data were available for 863 reports, and death was recorded in 97 reports [11.2% (95% CI, 9.3%\u201313.5%)]. Reported fatal outcomes were more frequent in women, patients aged \u226570 years, those with delayed onset (\u22658 days after COVID-19 vaccination), and those with \u22651 comorbidities. Multivariable logistic regression identified age \u226570 years as independently associated with reported fatal outcomes (OR 8.67, 95% CI 4.41\u201317.3; P &amp;lt; .001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Older age was associated with higher odds of reported fatal outcomes among VRM reports in JADER. Female sex, delayed onset, and comorbidities were more common among reports with fatal outcomes. These exploratory findings require validation in clinically adjudicated studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvag239","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:02:09Z","timestamp":1789473729000},"source":"Crossref","is-referenced-by-count":0,"title":["Prognostic factors associated with fatal outcomes in COVID-19 vaccine-related myocarditis"],"prefix":"10.1093","volume":"13","author":[{"given":"Tomomi","family":"Ueda","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo , Hongo 7-3-1, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2810-8040","authenticated-orcid":false,"given":"Eisuke","family":"Amiya","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo , Hongo 7-3-1, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]},{"name":"Department of Advanced Medical Center for Heart Failure, Graduate School of Medicine, The University of Tokyo , Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2135-3625","authenticated-orcid":false,"given":"Masaru","family":"Hatano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine and Endocrinology and Metabolism, Tottori University , Yonago, Tottori 683-8504 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo , Hongo 7-3-1, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Akazawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo , Hongo 7-3-1, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]},{"name":"Molecular Cardiovascular Medicine, Division of Innovative Research, Project Research Center, Medical Research Institute, Kanazawa Medical University , Uchinada, Ishikawa 920-0293 ,","place":["Japan"]},{"name":"Multidisciplinary Cancer Center, Kanazawa Medical University Hospital , Uchinada, Ishikawa 920-0293 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo , Hongo 7-3-1, Bunkyo-ku, Tokyo 113-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"2026101616272017200_xvag239-B1","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/jama.2023.3371","article-title":"Diagnosis and treatment of acute myocarditis: a review","volume":"329","author":"Ammirati","year":"2023","journal-title":"JAMA"},{"key":"2026101616272017200_xvag239-B2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1253\/circj.CJ-22-0696","article-title":"JCS 2023 guideline on the diagnosis and treatment of myocarditis","volume":"87","author":"Nagai","year":"2023","journal-title":"Circ J"},{"key":"2026101616272017200_xvag239-B3","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1056\/NEJMoa2110737","article-title":"Myocarditis after COVID-19 vaccination in a large health care organization","volume":"385","author":"Witberg","year":"2021","journal-title":"N Engl J Med"},{"key":"2026101616272017200_xvag239-B4","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1001\/jamacardio.2022.0583","article-title":"SARS-CoV-2 Vaccination and myocarditis in a nordic cohort study of 23 million residents","volume":"7","author":"Karlstad","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026101616272017200_xvag239-B5","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1001\/jama.2024.16380","article-title":"Long-term prognosis of patients with myocarditis attributed to COVID-19 mRNA vaccination, SARS-CoV-2 infection, or conventional Etiologies","volume":"332","author":"Semenzato","year":"2024","journal-title":"JAMA"},{"key":"2026101616272017200_xvag239-B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102809","article-title":"Cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in the USA: longitudinal results from the Myocarditis After COVID Vaccination (MACiV) multicenter study","volume":"76","author":"Jain","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026101616272017200_xvag239-B7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11886-024-02021-w","article-title":"Fulminant myocarditis temporally associated with COVID-19 vaccination","volume":"26","author":"Ammirati","year":"2024","journal-title":"Curr Cardiol Rep"},{"key":"2026101616272017200_xvag239-B8","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1161\/CIRCULATIONAHA.121.058869","article-title":"Features and outcomes of histologically proven myocarditis with fulminant presentation","volume":"146","author":"Kanaoka","year":"2022","journal-title":"Circulation"},{"key":"2026101616272017200_xvag239-B9","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/ejhf.2496","article-title":"Predictors of relapse, death or heart transplantation in myocarditis before the introduction of immunosuppression: negative prognostic impact of female gender, fulminant onset, lower ejection fraction and serum autoantibodies","volume":"24","author":"Baritussio","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026101616272017200_xvag239-B10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1751-0473-3-17","article-title":"Purposeful selection of variables in logistic regression","volume":"3","author":"Bursac","year":"2008","journal-title":"Source Code Biol Med"},{"key":"2026101616272017200_xvag239-B11","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1093\/eurheartj\/ehad339","article-title":"COVID-19 vaccination-related myocarditis: a Korean nationwide study","volume":"44","author":"Cho","year":"2023","journal-title":"Eur Heart J"},{"key":"2026101616272017200_xvag239-B12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.039673","article-title":"Prognostic factors associated with early recovery from veno-arterial extracorporeal membrane oxygenation support in patients with fulminant myocarditis","volume":"14","author":"Ueda","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"2026101616272017200_xvag239-B13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.010152","article-title":"Outcomes with peripheral venoarterial extracorporeal membrane oxygenation for suspected acute myocarditis: 10-year experience from the extracorporeal life support organization registry","volume":"16","author":"Nunez","year":"2023","journal-title":"Circ Heart Fail"},{"key":"2026101616272017200_xvag239-B14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamapediatrics.2022.4768","article-title":"Myopericarditis after COVID-19 mRNA vaccination among adolescents and young adults: a systematic review and meta-analysis","volume":"177","author":"Yasuhara","year":"2023","journal-title":"JAMA Pediatr"},{"key":"2026101616272017200_xvag239-B15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.17890","article-title":"A late presentation of COVID-19 vaccine-induced myocarditis","volume":"13","author":"Gautam","year":"2021","journal-title":"Cureus"},{"key":"2026101616272017200_xvag239-B16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008151","article-title":"Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination","volume":"12","author":"Watson","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026101616272017200_xvag239-B17","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.230743","article-title":"Assessment of myocardial 18F-FDG Uptake at PET\/CT in asymptomatic SARS-CoV-2-vaccinated and nonvaccinated patients","volume":"308","author":"Nakahara","year":"2023","journal-title":"Radiology"},{"key":"2026101616272017200_xvag239-B18","author":"Ministry of Health, Labour and Welfare, Japan"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvag239\/71090359\/xvag239.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/5\/xvag239\/71090359\/xvag239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/5\/xvag239\/71090359\/xvag239.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:28:02Z","timestamp":1792182482000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvag239\/8796197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,16]]},"published-print":{"date-parts":[[2026,8,27]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag239","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,27]]},"article-number":"xvag239"}}